Recent Advances in Multiple Myeloma with Dr. Dan Vogl

The treatment landscape for multiple myeloma is shifting at absolute lightning speed. In this episode, we dive deep into the latest clinical breakthroughs, emerging frontline standards, and the groundbreaking immunotherapies rapidly redefining patient care. Joining the conversation is Dr. Dan Vogl, Associate Professor of Medicine and Myeloma Specialist at Penn Medicine's Abramson Cancer Center. Together, we break down the complex balancing act between treatment efficacy, long-term toxicity, and modern sequencing strategy. We examine everything from the transition toward quadruplet induction therapy to the revolutionary potential of off-the-shelf T-cell engagers and personalized cellular therapies. KEY TAKEAWAYS FROM THIS EPISODE: The Evolution of Frontline Therapy: Moving from triplet regimens to quadruplet combinations, and how the addition of monoclonal antibodies like daratumumab is shaping expectations for newly diagnosed patients. The Overall Survival Confounding Dilemma: Why evaluating long-term survival metrics in clinical trials has become increasingly difficult, and why clinical endpoints like progression-free survival (PFS) remain a point of healthy debate among oncologists. Redefining Transplant Eligibility: Shifting the conversation away from binary age limits and toward a more comprehensive, nuanced assessment of patient frailty and functional resilience. The Rise of Bispecific Antibodies (TCEs): A clear look at how dual-targeting therapies work to engage the immune system, their expanding role in early relapse, and insights into Penn's ongoing trials testing fixed-duration vs. indefinite dosing. CAR T-Cell Therapy in Practice: Demystifying the logistical timeline, cellular manufacturing process, and profound clinical response rates of chimeric antigen receptor T-cell therapies, alongside a candid look at rare, long-term toxicities. The Future of Community-Based Oncology: How specialized care delivery models are scaling to bring advanced, high-stakes immunotherapies safely to regional hospitals and community cancer centers. If you find this deep dive into modern hematologic oncology helpful, please hit that subscribe button, leave a comment with your thoughts, and share the episode with colleagues or families navigating a multiple myeloma journey. Disclaimer: The information provided in this podcast is for educational and informational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare professional regarding any medical condition or treatment plan. #MultipleMyeloma #OncologyPodcast #CancerResearch